RSV vaccine, GSK and Canada
Mississauga: GSK's AREXVY (respiratory syncytial virus vaccine - recombinant, AS01E adjuvanted) has been approved in Canada ...
Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.
To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...
RSV season is upon us, which means thousands of children under five years of age and hundreds of thousands of adults will be ...
With RSV season approachgin, there are more options for those most susceptible to RSV, including a new vaccine and updated ...
GSK has lowered its vaccine sales forecast for the year because of weak demand for its new respiratory syncytial virus jab Arexvy, sending the pharmaceutical group’s shares down more than 3 per cent ...
GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults aged 50 to 59 ...
This update in the health sector highlights major developments including DiaSorin's significant profit growth, GSK's RSV ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback